Drug: Oxymorphone Extended Release: chronic pain clinical trials
Registry records that list "Drug: Oxymorphone Extended Release" as an intervention. Being studied does not mean an intervention works or is approved.
0
Trials with Canadian sites
0
Recruiting in Canada
4
Registry records in total
Trials in Canada
No trial with a Canadian site lists this intervention in this snapshot.
Trials worldwide (outside Canada)
4 trials, 0 recruiting or not yet recruiting. Recruiting first.
| Phase | Countries | ||||
|---|---|---|---|---|---|
| Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain NCT00225797 | Completed | Phase 3 | United States | Endo USA Inc., a Keenova Therapeutics Company | 2004-11 |
| Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain NCT00226421 | Completed | Phase 3 | United States | Endo USA Inc., a Keenova Therapeutics Company | 2004-10 |
| Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain NCT00911261 | Completed | Phase 3 | Endo USA Inc., a Keenova Therapeutics Company | 2003-08 | |
| Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain NCT00911287 | Completed | Phase 3 | Endo USA Inc., a Keenova Therapeutics Company | 2003-06 |
Conditions studied with this intervention
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.